Jun Muto, Hidetoshi Murata, Seiji Shigekawa, Takafumi Mitsuhara, Daisuke Umebayashi, Ryo Kanematsu, Masahiro Joko, Tatsushi Inoue, Tomoo Inoue, Toshiki Endo, Yuichi Hirose, for the Investigators of Intramedullary Spinal Cord Tumors in the Neurospinal Society of Japan
Neurospine 2023;20(3):774-782. Published online September 30, 2023
Objective The characteristics, imaging features, long-term surgical outcomes, and recurrence rates of primary spinal pilocytic astrocytomas (PAs) have not been clarified owing to their rarity and limited reports. Thus, this study aimed to analyze the clinical presentation, radiological features, pathological findings, and long-term outcomes of spinal PAs.
Methods Eighteen patients with spinal PAs who were surgically treated between 2009 and 2020 at 58 institutions were included in this retrospective multicenter study. Patient data, including demographics, radiographic features, treatment modalities, and long-term outcomes, were evaluated.
Results Among the 18 consecutive patients identified, 11 were women and 7 were men; the mean age at presentation was 31 years (3–73 years). Most PAs were located eccentrically, were solid or heterogeneous in appearance (cystic and solid), and had unclear margins. Gross total resection (GTR), subtotal resection (STR), partial resection (PR), and biopsy were performed in 28%, 33%, 33%, and 5% of cases, respectively. During a follow-up period of 65 ± 49 months, 4 patients developed a recurrence; however, the recurrence-free survival did not differ significantly between the GTR and non-GTR (STR, PR, and biopsy) groups.
Conclusion Primary spinal PAs are rare and present as eccentric and intermixed cystic and solid intramedullary cervical tumors. The imaging features of spinal PAs are nonspecific, and a definitive diagnosis requires pathological support. Surgical resection with prevention of neurological deterioration can serve as the first-line treatment; however, the resection rate does not affect recurrence-free survival. Investigation of relevant molecular biomarkers is required to elucidate the regrowth risk and prognostic factors.
Citations
Citations to this article as recorded by
Thoracic intramedullary spinal cord astrocytoma associated with syringomyelia: a case report of gross total resection Igin Ginting, Larona Hydravianto, Lukas Widhiyanto International Journal of Surgery Case Reports.2026; 138(3): 987. CrossRef
The 4S of spinal astrocytoma: specific location, syrinx, spasticity and score on Modified Mccormick Scale (MMS) predict long term outcomes in patients undergoing surgical resection of intramedullary spinal astrocytomas Bhavya Pahwa, Gaurav Singh, Shashank Sharad Kale Journal of Neuro-Oncology.2025; 171(1): 131. CrossRef
Current Treatment Outcomes for Intramedullary Spinal Cord Tumors in Japan Toshiki Endo, Yoshiharu Takahashi, Taketo Nishizawa, Akira Ito, Tatsuya Sasaki Japanese Journal of Neurosurgery.2025; 34(6): 327. CrossRef
The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors Ines Esparragosa Vazquez, François Ducray Cancers.2024; 16(16): 2781. CrossRef
Cervical Pilocytic Astrocytoma Mimicking Spondylotic Myelopathy: A Case Report and Literature Review Morgane M Soler-Rico, Lina Daoud, Edward Fomekong Cureus.2024;[Epub] CrossRef
The Inside Story of the Multi–center Studies in the Neurospinal Society of Japan Keisuke Takai Spinal Surgery.2024; 38(2): 105. CrossRef
Current Trends and Future Perspective of Intramedullary Spinal Cord Tumor Treatments Toshiki Endo, Yoshiharu Takahashi, Taketo Nishizawa, Tatsuya Sasaki Japanese Journal of Neurosurgery.2024; 33(6): 408. CrossRef
Ryo Kanematsu, Masaki Mizuno, Tomoo Inoue, Toshiyuki Takahashi, Toshiki Endo, Seiji Shigekawa, Jun Muto, Daisuke Umebayashi, Takafumi Mitsuhara, Kazutoshi Hida, Junya Hanakita, for the Investigators of Intramedullary Spinal Cord Tumors in the Neurospinal Society of Japan
Neurospine 2023;20(3):766-773. Published online September 30, 2023
Objective The impact of adjuvant radiotherapy on overall survival (OS) and progression-free survival (PFS) of patients with grade II spinal cord astrocytomas remains controversial. Additionally, the relationship between progression and clinical deterioration after radiotherapy has not been well investigated.
Methods This study included 53 patients with grade II intramedullary spinal cord astrocytomas treated by either subtotal, partial resection or open biopsy. Their clinical performance status was assessed immediately before operation and 1, 6, 12, 24, and 60 months after surgery by Karnofsky Performance Scale (KPS). Patients with and without adjuvant radiotherapy were compared.
Results The groups with and without radiation comprised 23 and 30 patients with a mean age of 50.3 ± 22.6 years (range, 2–88 years). The mean overall disease progression rate was 47.1% during a mean follow-up period of 48.4 ± 39.8 months (range, 2.5–144.5 months). In the radiation group, 11 patients (47.8%) presented with progressive disease, whereas 14 patients (46.7%) presented with progressive disease in the group without radiation. There were no significant differences in OS or PFS among patients with or without adjuvant radiotherapy. KPS in both groups, especially radiation group, gradually decreased after operation and deteriorated before the confirmation of disease progression.
Conclusion Adjuvant radiotherapy did not show effectiveness regarding PFS or OS in patients with grade II spinal cord astrocytoma according to classical classification based on pathohistological findings.
Citations
Citations to this article as recorded by
Intramedullary Spinal Cord Tumors in the Elderly Patient Max Ward, Ethan D.L. Brown, Apratim Maity, Sheng-Fu Larry Lo, Daniel M. Sciubba Neurosurgery Clinics of North America.2026; 37(3): 363. CrossRef
The 4S of spinal astrocytoma: specific location, syrinx, spasticity and score on Modified Mccormick Scale (MMS) predict long term outcomes in patients undergoing surgical resection of intramedullary spinal astrocytomas Bhavya Pahwa, Gaurav Singh, Shashank Sharad Kale Journal of Neuro-Oncology.2025; 171(1): 131. CrossRef
The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysis Victor Gabriel El-Hajj, Sruthi Ranganathan, Harry Hoang, Abdul Karim Ghaith, Mohamad Bydon, Adrian Elmi-Terander Journal of Neuro-Oncology.2025; 171(3): 629. CrossRef
Current Treatment Outcomes for Intramedullary Spinal Cord Tumors in Japan Toshiki Endo, Yoshiharu Takahashi, Taketo Nishizawa, Akira Ito, Tatsuya Sasaki Japanese Journal of Neurosurgery.2025; 34(6): 327. CrossRef
Molecular insights and the role of 18F-FDG-PET/CT in the diagnosis of spinal gliomas Yoshitaka Nagashima, Yusuke Nishimura, Kaoru Eguchi, Junya Yamaguchi, Shoichi Haimoto, Fumiharu Ohka, Kazuya Motomura, Takashi Abe, Mamoru Matsuo, Eisuke Tsukamoto, Masahito Hara, Ryuta Saito Acta Neurochirurgica.2024;[Epub] CrossRef
The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors Ines Esparragosa Vazquez, François Ducray Cancers.2024; 16(16): 2781. CrossRef
The Inside Story of the Multi–center Studies in the Neurospinal Society of Japan Keisuke Takai Spinal Surgery.2024; 38(2): 105. CrossRef
Spinal intramedullary tumors Belal Neyazi, Aiden Haghikia, Christian Mawrin, Elke Hattingen, Dirk Vordermark, I. Erol Sandalcioglu Deutsches Ärzteblatt international.2024;[Epub] CrossRef
Current Trends and Future Perspective of Intramedullary Spinal Cord Tumor Treatments Toshiki Endo, Yoshiharu Takahashi, Taketo Nishizawa, Tatsuya Sasaki Japanese Journal of Neurosurgery.2024; 33(6): 408. CrossRef
First
Prev
